AIM: To explore the effect of compound Xueshuantong capsule combined with calcium dobesilate in patients with early diabetic retinopathy.

METHODS: Totally 120 patients with early diabetic retinopathy were selected, and they were randomly divided into study group and control group according to the random number table method, each had 60 cases. Patients in the control group were treated with compound Xueshuantong capsule, and the patients in the study group were treated with compound Xueshuantong capsule combined with calcium dobesilate. We observed and compared the clinical symptoms(hemangioma volume, hemorrhagic spot area, macular thickness, visual gray value, visual acuity, threshold sensitivity within 30°), inflammatory factors(serum hs-CRP, VEGF, IGF-1), clinical efficacy and adverse events.

RESULTS:(1)The hematoma volume, hemorrhage spot area, macular thickness and visual gray value of the two groups were lower than those before treatment(t_{study group}=24.81, 19.59, 8.567, 17.79, t_{control group}=12.02, 8.60, 10.32, 10.85; P<0.05); visual acuity, threshold sensitivity within 30°were significantly higher than before(t_{study group}=-5.24, -8.79, t_{study group}=-2.26, -3.39; all P<0.05). After treatment, hemangioma volume, haemorrhagic area, macular thickness and visual gray value of the study group were lower than those of the control group, visual acuity and threshold sensitivity within 30°were higher than those of the control group(t=-12.97, -9.47,-13.54, -5.59, 2.65, 4.05; all P<0.05).(2)The levels of hs-CRP, VEGF and IGF-1 in the two groups were lower than those before treatment(t_{study group}=34.30, 23.33, 42.118, t_{control group} =18.68, 17.46, 26.73; all P<0.05). The levels of hs-CRP, VEGF and IGF-1 in the study group were significantly lower than those in the control group(t=-14.79, -7.43, -15.35, all P<0.05).(3)The total effective rate was 92.0% in the study group, which was higher than 70.8% in the control group(χ²=16.352, P<0.05).(4)The incidence of adverse reactions was 10% in the study group and 13% in the control group. There was no significant difference in the incidence of adverse reactions between the two groups(χ²=0.32, P>0.05).

CONCLUSION: Compound Xueshuantong capsule combined with calcium dobesilate in the treatment of early diabetic retinopathy can effectively improve the clinical symptoms of retinal defects, the mechanism of action is related to the level of inflammatory factors, the clinical efficacy is better, security is high.